Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Aug;135(8):784-8.
doi: 10.1001/archoto.2009.98.

Photodynamic therapy for head and neck dysplasia and cancer

Nestor R Rigual  1 , Krishnakumar Thankappan, Michele Cooper, Maureen A Sullivan, Thomas Dougherty, Saurin R Popat, Thom R Loree, Merrill A Biel, Barbara Henderson
Affiliations
Clinical Trial

Photodynamic therapy for head and neck dysplasia and cancer

Nestor R Rigual et al. Arch Otolaryngol Head Neck Surg. 2009 Aug.

Abstract

Objective: To determine the response of dysplasia, carcinoma in situ (CIS), and T1 carcinoma of the oral cavity and larynx to photodynamic therapy with porfimer sodium.

Design: Prospective trial.

Setting: A National Cancer Institute-designated cancer institute.

Patients: Patients with primary or recurrent moderate to severe oral or laryngeal dysplasia, CIS, or T1N0 carcinoma.

Intervention: Porfimer sodium, 2 mg/kg of body weight, was injected intravenously 48 hours before treatment. Light at 630 nm for photosensitizer activation was delivered from an argon laser or diode laser using lens or cylindrical diffuser fibers. The light dose was 50 J/cm(2) for dysplasia and CIS and 75 J/cm(2) for carcinoma.

Main outcome measures: Response was evaluated at 1 week and at 1 month and then at 3-month intervals thereafter. Response options were complete (CR), partial (PR), and no (NR) response. Posttreatment biopsies were performed in all patients with persistent and recurrent visible lesions.

Results: Thirty patients were enrolled, and 26 were evaluable. Mean follow-up was 15 months (range, 7-52 months). Twenty-four patients had a CR, 1 had a PR, and 1 had NR. Three patients with oral dysplasia with an initial CR experienced recurrence in the treatment field. All the patients with NR, a PR, or recurrence after an initial CR underwent salvage treatment. Temporary morbidities included edema, pain, hoarseness, and skin phototoxicity.

Conclusion: Photodynamic therapy with porfimer sodium is an effective treatment alternative, with no permanent sequelae, for oral and laryngeal dysplasia and early carcinoma.

Trial registration: clinicaltrials.gov Identifier: NCT00530088.

PubMed Disclaimer

Figures

Figure 1
Figure 1
One week after photodynamic therapy for recurrent squamous cell carcinoma and osteoradionecrosis.
Figure 2
Figure 2
Six months after photodynamic therapy.
See this image and copyright information in PMC

References

    1. Shah JP, Gil Z. Current concepts in management of oral cancer: surgery. Oral Oncol. 2009;45(4–5):394–401. - PMC - PubMed
    1. Hinerman RW, Mendenhall WM, Amdur RJ, Villaret DB, Robbins KT. Early laryngeal cancer. Curr Treat Options Oncol. 2002;3(1):3–9. - PubMed
    1. Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14(3):199–212. - PubMed
    1. Steiner W. Results of curative laser microsurgery of laryngeal carcinomas. Am J Otolaryngol. 1993;14(2):116–121. - PubMed
    1. Garcia-Serra A, Hinerman RW, Amdur RJ, Morris CG, Mendenhall WM. Radiotherapy for carcinoma in situ of the true vocal cords. Head Neck. 2002;24(4):390–394. - PubMed

Publication types

MeSH terms

Substances

Associated data